Bright Minds Biosciences Inc(DRUG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DRUG Bright Minds Biosciences Inc

Not Yet Opened 02-02 16:00:00 EST

78.64

+0.89

+1.14%

盘后78.64

+0.000.00%

18:51 EST

High83.35	Low77.00	Vol165.70K
Open77.21	D1 Closing77.75	Amplitude8.17%
Mkt Cap765.34M	Tradable Cap411.90M	Total Shares9.73M
T/O13.32M	T/O Rate3.16%	Tradable Shares5.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DRUG","market":"US","secType":"STK","nameCN":"Bright Minds Biosciences Inc","latestPrice":78.64,"timestamp":1770066000000,"preClose":77.75,"halted":0,"volume":165697,"hourTrading":{"tag":"盘后","latestPrice":78.64,"preClose":78.64,"latestTime":"18:51 EST","volume":369,"amount":29014.84,"timestamp":1770076309823,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.011446945337620586,"floatShares":5237800,"shares":9732200,"eps":-1.05653,"marketStatus":"Not Yet Opened","change":0.89,"latestTime":"02-02 16:00:00 EST","open":77.21,"high":83.35,"low":77,"amount":13323540.01482,"amplitude":0.081672,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.05653,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770109200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":77.75,"postHourTrading":{"tag":"盘后","latestPrice":78.64,"preClose":78.64,"latestTime":"18:51 EST","volume":369,"amount":29014.84,"timestamp":1770076309823,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.581736},"requestUrl":"/m/hq/s/DRUG","defaultTab":"news","newsList":[{"id":"2608991848","title":"BTIG Sticks to Its Buy Rating for Bright Minds Biosciences (DRUG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608991848","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608991848?lang=en_us&edition=fundamental","pubTime":"2026-02-03 10:47","pubTimestamp":1770086856,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Bright Minds Biosciences, with a price target of $147.00. Accor...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-bright-minds-biosciences-drug-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-bright-minds-biosciences-drug-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRUG"],"gpt_icon":0},{"id":"2602089403","title":"Bright Minds Biosciences Announces Closing of US$175 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2602089403","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602089403?lang=en_us&edition=fundamental","pubTime":"2026-01-10 00:56","pubTimestamp":1767977760,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan.  09, 2026  (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today closed its recently announced public offering of 1,945,00","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/09/3216228/0/en/Bright-Minds-Biosciences-Announces-Closing-of-US-175-Million-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","USA","DRUG"],"gpt_icon":0},{"id":"2601689339","title":"Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2601689339","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601689339?lang=en_us&edition=fundamental","pubTime":"2026-01-08 10:33","pubTimestamp":1767839580,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan.  07, 2026  (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the pricing of its previously announced public offeri","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215014/0/en/Bright-Minds-Biosciences-Announces-Pricing-of-Upsized-US-175-Million-Public-Offering-of-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRUG","BK4139","USA"],"gpt_icon":0},{"id":"2601780048","title":"Crude Oil Down 2%; ISM Services PMI Surges In December","url":"https://stock-news.laohu8.com/highlight/detail?id=2601780048","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601780048?lang=en_us&edition=fundamental","pubTime":"2026-01-08 01:25","pubTimestamp":1767806746,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/26/01/49761540/crude-oil-down-2-ism-services-pmi-surges-in-december","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU2023250504.SGD","BK4141","BK4139","LU1093756168.USD","LU0203201768.USD","IE00BKDWB100.SGD","LU1064131342.USD","IE00BK4W5L77.USD","LU0234572021.USD","LU0466842654.USD","LU1720051017.SGD","SG9999018865.SGD","LU0316494557.USD","LU0456855351.SGD","LU2746668461.USD","LU0823434740.USD","BK4198","LU2237443382.USD","LU2552382058.USD","LU0256863902.USD","IE00B4JS1V06.HKD","LU1267930730.SGD","BK4082","LU0432979614.USD","LU1551013342.USD","USAW.SI","LU0545562505.USD","LU0823416689.USD","LU2471134523.USD","LU0417517546.SGD","LU1917777945.USD","NQmain","IE00BJT1NW94.SGD","SG9999014880.SGD","LU2552382215.SGD","LU1868837136.USD","IE00B4R5TH58.HKD","LU2324357040.USD","SGXZ81514606.USD","BK4539","LU0266013472.USD","LU0106261372.USD","LU2063271972.USD","PSQ","IE00B1BXHZ80.USD","IE00BWXC8680.SGD","LU0353189763.USD","LU0683600562.USD","LU0708995401.HKD","LU1712237335.SGD","LU2237443978.SGD","LU1868836591.USD","LU0354030438.USD","LU0320765059.SGD","LU0109391861.USD","LU2471134952.CNY","SG9999015952.SGD","LU1069344957.HKD","GB00BDT5M118.USD","LU1868836757.USD","LU0471298777.SGD","LU2461242641.AUD","LU0943347566.SGD","IE00BJJMRY28.SGD","BK4533","IE00B2B36J28.USD","LU1623119135.USD","LU0006306889.USD","LU1551013425.SGD","LU1804176565.USD","SG9999015945.SGD","BK4516","IE00BJJMRX11.SGD","SGXZ99366536.SGD","LU2602419157.SGD","BK4534","LU2417539215.USD","LU1988902786.USD","LU0787776722.HKD","BK4599","IE0009355771.USD","SQQQ","LU0198837287.USD","LU0385154629.USD","LU2237443622.USD","LU2237443895.HKD","LU1127390331.HKD","IE00B775H168.HKD","LU2360106947.USD","LU2471134796.USD","LU2471134879.HKD","BK4007","LU2361044865.SGD","LU0640476718.USD","LU1989771016.USD","IE00B7KXQ091.USD","LU2237438978.USD","LU2552382132.HKD","LU2089984988.USD","LU0096364046.USD","LU0994945656.USD","LU1366192091.USD","LU1323610961.USD","LU2211815571.USD","LU1983299246.USD","IE00BFSS8Q28.SGD","LU2168564149.EUR","LU0320765992.SGD","LU2264538146.SGD","LU0882574055.USD","IE0002141913.USD","DRUG",".IXIC","IE00BN29S564.USD","LU2361045086.USD","IE00BFSS7M15.SGD","IE00BKPKM429.USD","LU0238689110.USD","PMI","LU2361044949.HKD","SGXZ31699556.SGD","LU1057294990.SGD","LU2087625088.SGD","LU0079474960.USD","LU1720051108.HKD","LU0122379950.USD","LU2236285917.USD","SG9999014898.SGD","LU2168564065.EUR","LU0689472784.USD","LU0094547139.USD","BK4581","LU0323591593.USD","LU1814569148.SGD","IE00BFTCPJ56.SGD","LU1043141123.HKD","LU2750360641.GBP","LU1868837300.USD","LU1093756325.SGD","TQQQ","SG9999014906.USD","IE00BJJMRZ35.SGD","SG9999017495.SGD","SG9999014914.USD","LU2491050071.SGD","IE00BK4W5M84.HKD","LU2106854487.HKD","LU2237443549.SGD","LU2462157665.USD","LU2746668974.SGD","LU2357305700.SGD","LU0426412945.USD","VTYX","NVIW.SI","SG9999015986.USD","LU1974910355.USD","LU0114720955.EUR","IE0004445239.USD","LU1035775433.USD","LU0109394709.USD","LU0061475181.USD","LU2168563687.JPY","LU2750360997.AUD","LU0786609619.USD","LU0058720904.USD","LU0097036916.USD","SG9999001176.USD","IE0005OL40V9.USD","LU2168564495.EUR","SG9999018857.SGD","LU0353189680.USD","LU1061106388.HKD","SG9999015978.USD","LU0289739699.SGD","MNQmain","USJW.SI","LU0672654240.SGD","GLUE","QLD","LU2456880835.USD","LU1232071149.USD","LU0426417589.USD","LU1868836914.USD","LU2491049909.HKD","LU0256863811.USD","IE00BJLML261.HKD","LU0820561909.HKD","LUCY","QID","LU2265009873.SGD","IE00B1XK9C88.USD","SG9999013999.USD","TSYW.SI","BK4588","LU0471298694.HKD","SG9999001176.SGD","CRIS","LU0889565916.HKD","IE0004445015.USD","LU1023059063.AUD","LU1280957306.USD","LU2112291526.USD","LU1548497426.USD","LU2168564222.USD","LU2468319806.SGD","SGXZ57979304.SGD","LU0820561818.USD","LU0882574139.USD","SGXZ51526630.SGD","BK4585","LU0823434583.USD","LU1291159041.SGD","LU2491050154.USD","LU0354030511.USD","LU2108987350.USD","LU0203202063.USD"],"gpt_icon":1},{"id":"2601221848","title":"Press Release: Bright Minds Biosciences Announces Launch of US$100 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2601221848","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601221848?lang=en_us&edition=fundamental","pubTime":"2026-01-07 05:00","pubTimestamp":1767733200,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan. 06, 2026  -- Bright Minds Biosciences Inc.    announces the launch of a public offering of common shares in the capital of the Company  and, in lieu of Common Shares to investors that so choose, pre-funded warrants  to purchase Common Shares, for aggregate gross proceeds of US$100 million . In connection with the Offering, the Company intends to grant to the underwriters, a 30-day option to purchase up to an additional 15% of the Common Shares issued in the Offering.The Company intends to use the net proceeds from the Offering to fund future clinical trials for the Company's drug candidates, including for absence seizures, DEE, and Prader-Willi Syndrome, as well as initiation of phase 1 clinical drug trials for BMB-105, and additional research and development work on earlier phase programs, as well as for general corporate and working capital purposes.Jefferies, TD Cowen, Piper Sandler & Co., and Cantor are acting as joint book-running managers for the Offering.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USA","BK4139","DRUG"],"gpt_icon":0},{"id":"2601814851","title":"New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2601814851","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601814851?lang=en_us&edition=fundamental","pubTime":"2026-01-07 00:52","pubTimestamp":1767718320,"startTime":"0","endTime":"0","summary":"Bright Minds' stock rose after its epilepsy drug cut seizures in a Phase 2 trial, showed good safety, and improved sleep, setting up plans for larger global studies.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/06/Woman-Hand-Holding-Healthcare-Medical-Ic.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/06/Woman-Hand-Holding-Healthcare-Medical-Ic.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/49730272/new-bright-minds-epilepsy-drug-cuts-seizures-lifts-stock-on-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/01/49730272/new-bright-minds-epilepsy-drug-cuts-seizures-lifts-stock-on-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","DRUG"],"gpt_icon":0},{"id":"2601819444","title":"Bright Minds Biosciences Up Over 24%, on Track for Record High Close -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2601819444","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601819444?lang=en_us&edition=fundamental","pubTime":"2026-01-07 00:19","pubTimestamp":1767716340,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences Inc.  is currently at $99.54, up $19.54 or 24.42%. --On pace for largest percent increase since Oct. 18, 2024, when it rose 117.56%. --Up 147.5% from 52 weeks ago , when it closed at $40.22. --Up 327.78% from its 52-week closing low of $23.27 on June 27, 2025. --Traded as high as $123.75; new all-time intraday high ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Bright Minds Biosciences Up Over 24%, on Track for Record High Close -- Data Talk","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DRUG"],"gpt_icon":0},{"id":"2601890818","title":"Bright Minds Biosciences Says Phase 2 Trial Results of BMB-101 Show 'Robust' Reduction in Seizure","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890818","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601890818?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:20","pubTimestamp":1767705644,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences  said Tuesday its phase 2 study of BMB-101, to treat absence seizures and developmental and encephalopathic epilepsies, met the primary efficacy endpoint by showing a \"robust\" seizure reduction with a \"favorable safety and tolerability\" profile.The trial enrolled a total of 24 participants and had a four-week baseline, four-week titration and maintenance period.The company said the patients demonstrated a 73% median reduction in the number of absence seizure in the absence seizure group. It was also found to be \"generally well tolerated\" and there were no treatment-related serious adverse effects seen.Bright Minds also said it has started preparations for global registrational trials in both absence seizures and developmental and encephalopathic epilepsies patients.Shares of the company were up 28% in recent Tuesday premarket activity.Price: 102.44, Change: +22.43, Percent Change: +28.03","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DRUG","BK4139","DRUG.AU"],"gpt_icon":0},{"id":"2601086401","title":"U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2601086401","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601086401?lang=en_us&edition=fundamental","pubTime":"2026-01-06 15:53","pubTimestamp":1767686032,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR InfrastructureJan 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL8N3Y7095:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD","LU2125154935.USD","BP","AGNC","AVY","ARVN","AGIO","SG9999014005.SGD","BA","ALNY","IE00B5TLWC47.USD","BK4532","BKNG","ADAM","ALHC","AIG","BMY","AAL","ARCT","BK4178","BOW","APGE","ALB","AXSM","BRLT","WMS","BIIB","BKD","LU0757428866.USD","SGXZ23171101.USD","LU0971096721.USD","BC","BLTE","EAT","ALL","BBWI","BBBY","ALGT","AMT","BALL","BBIO","BK4135","LU2249611893.SGD","AJG","NLY","AEO","DRUG","BAC","ALK","BK"],"gpt_icon":1},{"id":"2592969977","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2592969977","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592969977?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:00","pubTimestamp":1766055600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.FactSet Research Syss Inc.                       1Q      4.36   6:00 AM. Innovative Solutions and Support Inc.           4Q       .11       BMO. NIKE Inc. Class B                                2Q       .37   4:15 PM. Lamb Weston Hldgs Inc.                            2Q       .64   8:30 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2506952097.USD","PAYX","NNE","LU0545039389.USD","FCEL","CAG","DRI","DRUG","LU0786609619.USD","LU2506951958.HKD","LU1228905037.USD","IE00BJJMRY28.SGD","BIRK","WGO","LU0154245756.USD","LU0868494708.USD","FDS","HEI.A","BK4588","IE00BYQQ9H92.USD","LU0310800965.SGD","NKE","KBH","ISSC","LU1366333091.USD","BK4561","ACN","BK4146","LU0823417737.USD","BK4547","LU0052756011.USD","LU1823568750.SGD","LU1989772923.USD","KMX","IE00BVYPNV92.GBP","LU2506951875.HKD","BK4566","BK4534","OTLK","IE00BFXG0V08.USD","LW","HEI","CUK","BK4212","BK4112","CTAS","FDX","LU0823417653.USD","BK4524"],"gpt_icon":1},{"id":"2591648985","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648985","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591648985?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:00","pubTimestamp":1765796400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Enerpac Tool Grp Corp Class A                   1Q       .37       AMC. FactSet Research Syss Inc.                       1Q      4.36   6:00 AM. Innovative Solutions and Support Inc.           4Q       .11       BMO. NIKE Inc. Class B                                2Q       .38   4:15 PM. Lamb Weston Hldgs Inc.                            2Q       .64   8:30 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEI.A","MLKN","JBL","WOR","LEN/WD","AMC","BK4131","DRI","KMX","BIRK","HEI","DRUG","LU0950375773.USD","AMCDD","PAYX","LU1046421795.USD","BK4209","BK4553","OGI","CUK","IE00BJJMRX11.SGD","IE00BSNM7G36.USD","KBH","BK4152","LU0056508442.USD","TTC","WGO","CTAS","BK4567","LU1235294995.USD","EPAC","OTLK","VERU","LU0323240290.USD","NKE","FCEL","FDX","FDS","ABM","CAG","GIS","LEN","LEN.B","NAVN","ACN","MU","ISSC","LW","SG9999004303.SGD","BK4130"],"gpt_icon":1},{"id":"2584405726","title":"Press Release: Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584405726","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584405726?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:50","pubTimestamp":1763380200,"startTime":"0","endTime":"0","summary":"-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support the Company's PWS program, which was announced on November 6, 2025 --. NEW YORK and VANCOUVER, British Columbia, Nov. 17, 2025  -- Bright Minds Biosciences Inc.    today announced the addition of four global experts in Prader-Willi Syndrome  to its Scientific Advisory Board :. On November 6, 2025, the Company held a KOL event to announce the initiation of its PWS program and the nomination of BMB-105 as a new clinical candidate. A replay of the presentation is available in the Investor section of the Company's website under News & Events.Dr. Jennifer Miller is a Professor in the division","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1721428933.USD","LU2413666699.HKD","IE00BYQQ9H92.USD","LU2211817866.USD","BK4588","LU1093756168.USD","LU2413666426.HKD","IE00BFXG0V08.USD","LU1093756325.SGD","FPWR","BK4567","BK4139","BK4548","BK4533","MTD","BK4121","DRUG","BK4585","LU0347712357.USD","PWS"],"gpt_icon":0},{"id":"2579101854","title":"Bright Minds Biosciences to Present at Upcoming Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2579101854","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579101854?lang=en_us&edition=fundamental","pubTime":"2025-10-31 06:30","pubTimestamp":1761863400,"startTime":"0","endTime":"0","summary":"NEW YORK, Oct.  30, 2025  (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3178037/0/en/Bright-Minds-Biosciences-to-Present-at-Upcoming-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4139","DRUG","BK4135"],"gpt_icon":0},{"id":"2565882696","title":"Bright Minds Biosciences Inc : Btig Initiates Coverage With Buy Rating; Target Price $72","url":"https://stock-news.laohu8.com/highlight/detail?id=2565882696","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565882696?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:40","pubTimestamp":1757328049,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nFWN3UV0W6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DRUG"],"gpt_icon":0},{"id":"2565851555","title":"Bright Minds Biosciences Enters Deal for $100 Million At-The-Market Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2565851555","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565851555?lang=en_us&edition=fundamental","pubTime":"2025-09-05 16:46","pubTimestamp":1757062009,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences  said late Thursday it has entered an agreement with Piper Sandler and Cantor Fitzgerald to establish an at-the-market equity offering of up to $100 million.The program will run for three years, the company said.Bright Minds intends to use any funds raised for general corporate purposes, it said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DRUG","DRUG.AU","BK4139"],"gpt_icon":0},{"id":"2564090374","title":"Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2564090374","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564090374?lang=en_us&edition=fundamental","pubTime":"2025-09-04 20:30","pubTimestamp":1756989000,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept.  04, 2025  (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG) today announced compelling preclinical results for its investigational compound BMB201, in a validated isoso","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/04/3144527/0/en/Bright-Minds-Biosciences-Announces-BMB-201-Outperforms-Sumatriptan-in-Validated-Preclinical-Vascular-Headache-Model.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRUG","BK4139"],"gpt_icon":0},{"id":"2562724971","title":"Bright Minds Biosciences to Present at Upcoming Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2562724971","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562724971?lang=en_us&edition=fundamental","pubTime":"2025-08-25 20:00","pubTimestamp":1756123200,"startTime":"0","endTime":"0","summary":"NEW YORK, Aug.  25, 2025  (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/25/3138410/0/en/Bright-Minds-Biosciences-to-Present-at-Upcoming-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNS","BK4135","DRUG"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.brightmindsbio.com","stockEarnings":[{"period":"1week","weight":-0.0872},{"period":"1month","weight":-0.0578},{"period":"3month","weight":0.5332},{"period":"6month","weight":1.2096},{"period":"1year","weight":1.3129},{"period":"ytd","weight":0.0077}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.099},{"period":"1year","weight":0.1555},{"period":"ytd","weight":0.0198}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.037856},{"month":2,"riseRate":0.4,"avgChangeRate":-0.079741},{"month":3,"riseRate":0,"avgChangeRate":-0.218801},{"month":4,"riseRate":0.25,"avgChangeRate":-0.074949},{"month":5,"riseRate":0.5,"avgChangeRate":0.068312},{"month":6,"riseRate":0.25,"avgChangeRate":-0.114262},{"month":7,"riseRate":1,"avgChangeRate":0.265332},{"month":8,"riseRate":0.5,"avgChangeRate":0.127885},{"month":9,"riseRate":0.5,"avgChangeRate":0.012143},{"month":10,"riseRate":0.25,"avgChangeRate":9.6378},{"month":11,"riseRate":0.5,"avgChangeRate":0.078078},{"month":12,"riseRate":0.4,"avgChangeRate":-0.11205}],"exchange":"NASDAQ","name":"Bright Minds Biosciences Inc","nameEN":"Bright Minds Biosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bright Minds Biosciences Inc(DRUG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Bright Minds Biosciences Inc(DRUG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Bright Minds Biosciences Inc,DRUG,Bright Minds Biosciences Inc股票,Bright Minds Biosciences Inc股票老虎,Bright Minds Biosciences Inc股票老虎国际,Bright Minds Biosciences Inc行情,Bright Minds Biosciences Inc股票行情,Bright Minds Biosciences Inc股价,Bright Minds Biosciences Inc股市,Bright Minds Biosciences Inc股票价格,Bright Minds Biosciences Inc股票交易,Bright Minds Biosciences Inc股票购买,Bright Minds Biosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bright Minds Biosciences Inc(DRUG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Bright Minds Biosciences Inc(DRUG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction